277 related articles for article (PubMed ID: 32516116)
1. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy.
Solinas C; Gu-Trantien C; Willard-Gallo K
ESMO Open; 2020 Jan; 5(1):. PubMed ID: 32516116
[TBL] [Abstract][Full Text] [Related]
2. Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment.
Boggio E; Gigliotti CL; Moia R; Scotta A; Crespi I; Boggione P; De Paoli L; Deambrogi C; Garzaro M; Vidali M; Chiocchetti A; Stoppa I; Rolla R; Dianzani C; Monge C; Clemente N; Gaidano G; Dianzani U
Br J Haematol; 2022 Mar; 196(6):1369-1380. PubMed ID: 34954822
[TBL] [Abstract][Full Text] [Related]
3. Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis.
Yan X; Gu Y; Wang C; Sun S; Wang X; Tian J; Wang M; Ji X; Duan X; Gao H; Fang Q; Dong W; Zhang X; Xue Q
Clin Immunol; 2019 Oct; 207():68-78. PubMed ID: 31374257
[TBL] [Abstract][Full Text] [Related]
4. Deep Flow Cytometry Unveils Distinct Immune Cell Subsets in Inducible T Cell Co-Stimulator Ligand (ICOSL)- and ICOS-Knockout Mice during Experimental Autoimmune Encephalomyelitis.
Raineri D; Abreu H; Vilardo B; Kustrimovic N; Venegoni C; Cappellano G; Chiocchetti A
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473756
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of ICOS ligand by interaction with ICOS functions as a regulatory mechanism for immune responses.
Watanabe M; Takagi Y; Kotani M; Hara Y; Inamine A; Hayashi K; Ogawa S; Takeda K; Tanabe K; Abe R
J Immunol; 2008 Apr; 180(8):5222-34. PubMed ID: 18390703
[TBL] [Abstract][Full Text] [Related]
6. Inducible costimulator (ICOS) and ICOS ligand signaling has pivotal roles in skin wound healing via cytokine production.
Maeda S; Fujimoto M; Matsushita T; Hamaguchi Y; Takehara K; Hasegawa M
Am J Pathol; 2011 Nov; 179(5):2360-9. PubMed ID: 21925472
[TBL] [Abstract][Full Text] [Related]
7. Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy.
Amatore F; Gorvel L; Olive D
Expert Opin Biol Ther; 2020 Feb; 20(2):141-150. PubMed ID: 31738626
[No Abstract] [Full Text] [Related]
8. Comprehensive analysis of the role of ICOS ( CD278 ) in pan-cancer prognosis and immunotherapy.
Zhao X; Wang Y; Jiang X; Mo B; Wang C; Tang M; Rong Y; Zhang G; Hu M; Cai H
BMC Cancer; 2023 Feb; 23(1):194. PubMed ID: 36855091
[TBL] [Abstract][Full Text] [Related]
9. Anti-ICOSL New Antigen Receptor Domains Inhibit T Cell Proliferation and Reduce the Development of Inflammation in the Collagen-Induced Mouse Model of Rheumatoid Arthritis.
O'Dwyer R; Kovaleva M; Zhang J; Steven J; Cummins E; Luxenberg D; Darmanin-Sheehan A; Carvalho MF; Whitters M; Saunders K; Barelle CJ
J Immunol Res; 2018; 2018():4089459. PubMed ID: 30417018
[TBL] [Abstract][Full Text] [Related]
10. Structural basis of inducible costimulator ligand costimulatory function: determination of the cell surface oligomeric state and functional mapping of the receptor binding site of the protein.
Chattopadhyay K; Bhatia S; Fiser A; Almo SC; Nathenson SG
J Immunol; 2006 Sep; 177(6):3920-9. PubMed ID: 16951355
[TBL] [Abstract][Full Text] [Related]
11. ICOS-Fc as innovative immunomodulatory approach to counteract inflammation and organ injury in sepsis.
Alves GF; Stoppa I; Aimaretti E; Monge C; Mastrocola R; Porchietto E; Einaudi G; Collotta D; Bertocchi I; Boggio E; Gigliotti CL; Clemente N; Aragno M; Fernandes D; Cifani C; Thiemermann C; Dianzani C; Dianzani U; Collino M
Front Immunol; 2022; 13():992614. PubMed ID: 36119089
[TBL] [Abstract][Full Text] [Related]
12. Expression and prognosis of inducible T-cell co-stimulator and its ligand in Chinese stage I-III lung adenocarcinoma patients.
Zhan XK; Liu XK; Zhang S; Chen H
Animal Model Exp Med; 2023 Oct; 6(5):464-473. PubMed ID: 37850501
[TBL] [Abstract][Full Text] [Related]
13. Inducible T-Cell Costimulator Mediates Lymphocyte/Macrophage Interactions During Liver Repair.
Ramavath NN; Gadipudi LL; Provera A; Gigliotti LC; Boggio E; Bozzola C; Albano E; Dianzani U; Sutti S
Front Immunol; 2021; 12():786680. PubMed ID: 34925367
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of experimental melanoma with ICOS-Fc loaded in biocompatible and biodegradable nanoparticles.
Clemente N; Boggio E; Gigliotti LC; Raineri D; Ferrara B; Miglio G; Argenziano M; Chiocchetti A; Cappellano G; Trotta F; Caldera F; Capucchio MT; Yagi J; Rojo MJ; Renò F; Cavalli R; Dianzani C; Dianzani U
J Control Release; 2020 Apr; 320():112-124. PubMed ID: 31962094
[TBL] [Abstract][Full Text] [Related]
15. Inducible costimulator ligand regulates bleomycin-induced lung and skin fibrosis in a mouse model independently of the inducible costimulator/inducible costimulator ligand pathway.
Tanaka C; Fujimoto M; Hamaguchi Y; Sato S; Takehara K; Hasegawa M
Arthritis Rheum; 2010 Jun; 62(6):1723-32. PubMed ID: 20191584
[TBL] [Abstract][Full Text] [Related]
16. ICOS/ICOSL upregulation mediates inflammatory response and endothelial dysfunction in type 2 diabetes mellitus.
Zhang HY; Ruan LB; Li Y; Yang TR; Liu WJ; Jiang YX; Li TR; Quan J; Xuan W
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8898-8908. PubMed ID: 30575933
[TBL] [Abstract][Full Text] [Related]
17. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy.
Amatore F; Gorvel L; Olive D
Expert Opin Ther Targets; 2018 Apr; 22(4):343-351. PubMed ID: 29468927
[TBL] [Abstract][Full Text] [Related]
18. Acute Myeloid Leukemia Cells Express ICOS Ligand to Promote the Expansion of Regulatory T Cells.
Han Y; Dong Y; Yang Q; Xu W; Jiang S; Yu Z; Yu K; Zhang S
Front Immunol; 2018; 9():2227. PubMed ID: 30319662
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of experimental autoimmune myocarditis by blocking activated T cells through inducible costimulatory molecule pathway.
Futamatsu H; Suzuki J; Kosuge H; Yokoseki O; Kamada M; Ito H; Inobe M; Isobe M; Uede T
Cardiovasc Res; 2003 Jul; 59(1):95-104. PubMed ID: 12829180
[TBL] [Abstract][Full Text] [Related]
20. An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression.
Sainson RCA; Thotakura AK; Kosmac M; Borhis G; Parveen N; Kimber R; Carvalho J; Henderson SJ; Pryke KL; Okell T; O'Leary S; Ball S; Van Krinks C; Gamand L; Taggart E; Pring EJ; Ali H; Craig H; Wong VWY; Liang Q; Rowlands RJ; Lecointre M; Campbell J; Kirby I; Melvin D; Germaschewski V; Oelmann E; Quaratino S; McCourt M
Cancer Immunol Res; 2020 Dec; 8(12):1568-1582. PubMed ID: 32999002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
